ClinicalTrials.gg
Status unknownNCT03641352Updated Aug 22, 2018

The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

A Phase 3 interventional study of CKD-501 0.5mg and Placebo in Type2 Diabetes, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-22.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
2nd of 23
240 · median 41
Started
2018
with 3 others
Phase 3
5 of 23
none open now
Registered
16th of 23
by date
Lead sponsor
20 of 23
Chong Kun Dang Pharmaceutical

Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

About lobeglitazone

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.

Read the detailed description

The aim of this phase 3 study was to evaluate the efficacy and safety of additional combined CKD-501 administration for 24 weeks in patient with type 2 diabetes who were nao adequately controlled for blood glucose by the combination of D150 and D759

03

Conditions studied

  • Type2 Diabetes
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 19 years and 80 years old(male or female)
  • Type 2 diabetes mellitus
  • The patient who has been taking oral hypoglycemic agent at least 8weeks with 7 to 10% at screening test
  • between 21kg/m2 and 40kg/m2
  • C-peptide ≥ 1.0 ng/ml
  • Agreement with written
  • HbA1c 7 to 10% after Run-in period

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus or secondary diabetes mellitus
  • Continuous or non continuous treatment(over 7 days) insulin within 3 months prior to screening
  • Treatment with Thiazolidinedione(TZD) within 3 months or patient who has experience such as reaction, serious adverse event with TZD, Biguanide
  • Chronic(continuous over 7 days) oral or non oral treatment within 1 month prior to screening
  • Treatment with anti-obesity drugs within 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    CKD-501 0.5mg

    CKD-501 0.5mg

    Drug: CKD-501 0.5mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759

    Also known as: Lobeglitazone

  • DrugPlacebo

    Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).

06

What researchers measure

Primary outcomes

  1. Change from baseline in Glycosylated Hemoglobin

    Time frame: Baseline, 24weeks

Secondary outcomes

  1. Change from baseline in in Glycosylated Hemoglobin

    Time frame: Baseline, 52weekes

  2. Change from baseline in Fasting plasma glucose

    Time frame: Baseline, 24weeks, 52weeks

  3. HbA1c target achievement rate at 24weekes(HbA1c < 6.5%, 7%)

    Time frame: Baseline, 24weeks

  4. Change from baseline in Total Cholesterol

    Time frame: Baseline, 24weeks, 52weeks

  5. Evaluate safety of CKD-501 from number of participants with adverse events

    Time frame: Baseline, 24weeks, 52weeks

  6. Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance)

    Time frame: Baseline, 24weeks, 52weeks

  7. Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function)

    Time frame: Baseline, 24 weeks, 52 weeks

  8. Change from baseline in QUICKI(Quantitative Insulin Check Index)

    Time frame: Baseline, 24 weeks, 52 weeks

  9. Change from baseline in Triglycerides

    Time frame: Baseline, 24 weeks, 52 weeks

  10. Change from baseline in LDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52 weeks

  11. Change from baseline in HDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52 weeks

  12. Change from baseline in non-HDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52 weeks

  13. Change from baseline in Small Dense LDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52 weeks

  14. Change from baseline in FFA(Free Fatty Acid)

    Time frame: Baseline, 24 weeks, 52 weeks

  15. Change from baseline in Apo-B

    Time frame: Baseline, 24 weeks, 52 weeks

  16. Change from baseline in Apo-CⅢ

    Time frame: Baseline, 24 weeks, 52 weeks

  17. Change from baseline in Apo-AⅠ

    Time frame: Baseline, 24 weeks, 52 weeks

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Korea, Seoul ST. Mary's Hospital
    Seoul, Korea, Republic of
    Recruiting
    • kun ho yoon, Ph.D · Contact82-2-2258-6007
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Apr 2021, 35 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 35 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Aug 22, 2018
StartActual
May 2, 2018
Primary completionEst.
Apr 30, 2021
CompletionEst.
Nov 30, 2022
Last update
Aug 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03641352
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
May 2, 2018
Primary completion
Apr 30, 2021 (estimated)
Completion
Nov 30, 2022 (estimated)
Last update
Aug 22, 2018

Study contacts

Kun ho Yoon, Ph.D
Contact
yoonk@catholic.ac.kr
82-2-2258-6007
Kun ho Yoon, Ph.D
principal investigator · The Catholic University of Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion